Alaunos Therapeutics
TCRT
100 hedge funds and large institutions have $34.2M invested in Alaunos Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 13 closing their positions.
2,046% more call options, than puts
Call options by funds: $4.12M | Put options by funds: $192K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.2% → 0.19% (-0.01%)
7% less funds holding
Funds holding: 108 → 100 (-8)
23% less capital invested
Capital invested by funds: $44.6M → $34.2M (-$10.4M)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$204K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$63.6K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$59.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$54.6K |
| 5 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$679K |
| 2 |
Two Sigma Advisers
New York
|
-$476K |
| 3 |
Two Sigma Investments
New York
|
-$304K |
| 4 |
MCA
Magnolia Capital Advisors
Jackson,
Mississippi
|
-$283K |
| 5 |
Renaissance Technologies
New York
|
-$279K |
TCRT Hedge Fund Activity: Q2 2023 in Review
100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2023, worth a combined $34.2M — down 23% from $44.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TCRT and 5 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 19 added.
The largest buyer was GSA Capital Partners, adding an estimated $204K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $679K sold.
- 100 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2023, down from 108 in Q1 2023.
- Funds reported $34.2M of Alaunos Therapeutics stock for Q2 2023, down 23% quarter-over-quarter.
- 5 funds opened new Alaunos Therapeutics positions in Q2 2023 and 13 closed out, a net change of -8 holders.
- The largest Alaunos Therapeutics buyer in Q2 2023 was GSA Capital Partners, an estimated $204K added.
- The largest Alaunos Therapeutics seller in Q2 2023 was Jacobs Levy Equity Management, an estimated $679K sold.
Based on aggregated 13F filings for Q2 2023.